SK279224B6 - Imidazolylmetylpyridín, spôsob jeho prípravy, tent - Google Patents
Imidazolylmetylpyridín, spôsob jeho prípravy, tent Download PDFInfo
- Publication number
- SK279224B6 SK279224B6 SK2896-92A SK289692A SK279224B6 SK 279224 B6 SK279224 B6 SK 279224B6 SK 289692 A SK289692 A SK 289692A SK 279224 B6 SK279224 B6 SK 279224B6
- Authority
- SK
- Slovakia
- Prior art keywords
- formula
- pyridine
- hydrogen
- acid addition
- free base
- Prior art date
Links
- SQEUYNQLUMQWKJ-UHFFFAOYSA-N 2-(1h-imidazol-2-ylmethyl)pyridine Chemical compound C=1C=CC=NC=1CC1=NC=CN1 SQEUYNQLUMQWKJ-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 239000003814 drug Substances 0.000 title claims description 5
- 150000003222 pyridines Chemical class 0.000 title description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title description 2
- 150000003839 salts Chemical group 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
- 239000012458 free base Substances 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- -1 2-methylimidazol-1-yl Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 8
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 239000000935 antidepressant agent Substances 0.000 abstract description 2
- 229940005513 antidepressants Drugs 0.000 abstract description 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002398 materia medica Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000003902 lesion Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000000627 locus coeruleus Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020651 Hyperkinesia Diseases 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- RFCSETTWLMSWED-UHFFFAOYSA-N CC1=NC=CN1C1=CC=CN=C1C Chemical compound CC1=NC=CN1C1=CC=CN=C1C RFCSETTWLMSWED-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011672 OFA rat Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Luminescent Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4131584A DE4131584A1 (de) | 1991-09-23 | 1991-09-23 | Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK289692A3 SK289692A3 (en) | 1998-08-05 |
| SK279224B6 true SK279224B6 (sk) | 1998-08-05 |
Family
ID=6441240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK2896-92A SK279224B6 (sk) | 1991-09-23 | 1992-09-21 | Imidazolylmetylpyridín, spôsob jeho prípravy, tent |
Country Status (24)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10165349A (ja) * | 1996-12-06 | 1998-06-23 | Matsushita Electric Ind Co Ltd | 食器洗浄機 |
| DE10000161A1 (de) * | 2000-01-06 | 2001-07-19 | Boehringer Ingelheim Pharma | Verfahren zur Identifikation eines Proteaseinhibitors |
| GB0009037D0 (en) * | 2000-04-13 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2555386A1 (en) * | 2004-02-19 | 2005-09-01 | Novartis Ag | Use of cholinesterase inhibitors for treating vascular depression |
| KR101146807B1 (ko) * | 2005-07-29 | 2012-05-21 | 반다 파마슈티칼즈, 인코퍼레이티드. | 각성을 향상시키는 방법 |
| CN101394849A (zh) * | 2006-02-13 | 2009-03-25 | Vanda制药公司 | 咪唑基烷基-吡啶的稳定的剂量制剂 |
| WO2009097416A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Imidazolylalkyl- pyridines as dbh inhibitors |
| EP2337788B1 (en) | 2008-10-17 | 2016-03-23 | Wisconsin Alumni Research Foundation | Method of making biologically active alpha-beta peptides |
| WO2012052540A1 (en) * | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
| JP2020520952A (ja) * | 2017-05-22 | 2020-07-16 | トーリー パインズ インスティテュート フォー モレキュラー スタディーズＴｏｒｒｅｙ Ｐｉｎｅｓ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｍｏｌｅｃｕｌａｒ Ｓｔｕｄｉｅｓ | 組成物、使用方法、及び治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2862340D1 (en) * | 1978-02-01 | 1983-11-24 | Wellcome Found | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof |
| GB2028317B (en) * | 1978-08-15 | 1982-11-10 | Pfizer Ltd | 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors |
| US4634711A (en) * | 1985-08-02 | 1987-01-06 | Smithkline Beckman Corporation | Pyridylalkyl imidazole-2-thiols |
| DE3811574A1 (de) * | 1988-03-31 | 1989-10-19 | Schering Ag | N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
-
1991
- 1991-09-23 DE DE4131584A patent/DE4131584A1/de not_active Withdrawn
-
1992
- 1992-09-09 HU HU9202886A patent/HUT61993A/hu unknown
- 1992-09-18 MY MYPI92001673A patent/MY110450A/en unknown
- 1992-09-21 AT AT92810719T patent/ATE144509T1/de active
- 1992-09-21 DE DE59207425T patent/DE59207425D1/de not_active Expired - Lifetime
- 1992-09-21 CA CA002078700A patent/CA2078700C/en not_active Expired - Fee Related
- 1992-09-21 EP EP92810719A patent/EP0534904B1/de not_active Expired - Lifetime
- 1992-09-21 NZ NZ244420A patent/NZ244420A/xx not_active IP Right Cessation
- 1992-09-21 ES ES92810719T patent/ES2092666T3/es not_active Expired - Lifetime
- 1992-09-21 SG SG1996003366A patent/SG43079A1/en unknown
- 1992-09-21 AU AU25226/92A patent/AU650569B2/en not_active Ceased
- 1992-09-21 NO NO923653A patent/NO301162B1/no not_active IP Right Cessation
- 1992-09-21 DK DK92810719.2T patent/DK0534904T3/da active
- 1992-09-21 SK SK2896-92A patent/SK279224B6/sk not_active IP Right Cessation
- 1992-09-21 FI FI924233A patent/FI103887B/fi not_active IP Right Cessation
- 1992-09-21 IL IL10322992A patent/IL103229A/en not_active IP Right Cessation
- 1992-09-21 CZ CS922896A patent/CZ281675B6/cs not_active IP Right Cessation
- 1992-09-22 MX MX9205365A patent/MX9205365A/es unknown
- 1992-09-22 RO RO92-01218A patent/RO109337B1/ro unknown
- 1992-09-22 KR KR1019920017228A patent/KR100254085B1/ko not_active Expired - Fee Related
- 1992-09-22 RU SU925052552A patent/RU2058312C1/ru active
- 1992-09-22 JP JP4252692A patent/JP2568356B2/ja not_active Expired - Fee Related
- 1992-09-23 ZA ZA927279A patent/ZA927279B/xx unknown
- 1992-09-24 TW TW081107550A patent/TW222630B/zh active
-
1995
- 1995-06-13 HU HU95P/P00198P patent/HU211261A9/hu unknown
-
1996
- 1996-10-24 GR GR960402593T patent/GR3021444T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4374841A (en) | Pyridoxine derivatives, and use in therapeutics | |
| AU684537B2 (en) | Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same | |
| JPS63146874A (ja) | インドール誘導体 | |
| US5001134A (en) | Piperidines, processes of preparation and medications containing them | |
| SK279224B6 (sk) | Imidazolylmetylpyridín, spôsob jeho prípravy, tent | |
| US5342960A (en) | Azomethines agonist compounds of the histamine H3 receptor for therapeutic use, pharmaceutical compositions acting as agonists of the said receptor and preparation process | |
| DE69736890T2 (de) | Kondensierte heterozyklische verbindungen und ihre pharmazeutische anwendung | |
| US4565816A (en) | Piperazine derivatives and pharmaceutical composition containing them | |
| US5635521A (en) | Imidazolylmethyl-pyridines | |
| DE69201184T2 (de) | 5- Piperazinylalkyl-1,5-Benzothiazepinone verwendbar als Calciumantagonisten. | |
| EP1120410B1 (en) | Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors | |
| JPH05271208A (ja) | １，４‐ベンゾチアゼピン誘導体 | |
| EP0314275A2 (en) | 2-Pyrrolidone-5-carboxylic acid compounds | |
| SK281387B6 (sk) | Deriváty kyseliny hydroxímovej, farmaceutický prostriedok, ktorý ich obsahuje, spôsob ich prípravy a medziprodukty na ich prípravu | |
| EP1261588B1 (en) | IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS | |
| US6388090B2 (en) | Imidazole derivatives | |
| US4237135A (en) | 2-(4-Ethyl-1-piperazinyl)-4-phenylquinoline, process for preparation thereof, and composition thereof | |
| JPH05500958A (ja) | 神経保護剤用イミノメタノジベンゾ（ａ，ｄ）シクロヘプテン誘導体 | |
| DE68913167T2 (de) | Indol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. | |
| DE69707080T2 (de) | Pyrrolidinonderivate und ihre Verwendung als antipsychotische Arzneimittel | |
| DE69324794T2 (de) | Phenyl imidazolinon-derivate, verfahren zu ihrer herstellung und ihre verwendung als 5-ht3-rezeptor-antagonisten | |
| US5508401A (en) | Substituted dibenzo[a,d]cycloheptene NMDA antagonists | |
| EP0182271B1 (de) | Neue Nb-quartäre Dibromderivate von Ajmalin, Isoajmalin, Sandwicin und Isosandwicin sowie diese Derivate enthaltende pharmazeutische Zubereitungen und Zwischenprodukte und Verfahren zu ihrer Herstellung | |
| CZ289526B6 (cs) | (S) nebo (R) Enantiomer piperazinylové sloučeniny a způsob jeho přípravy | |
| DE69320542T2 (de) | Pyrrolothienopyrazin-Verbindungen als 5HT3-Rezeptoren-Antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20110921 |